Trishula Therapeutics, Inc.. gastroesophageal junction ciwon daji. An gabatar da sakamakon binciken a cikin gabatarwar baka a ฦungiyar Amirka don Binciken Ciwon daji (AACR) Taron Shekara-shekara a New Orleans. Bayanan da aka gabatar ya nuna cewa TTX-1 hade da jiyya an yi haฦuri sosai kuma ya nuna alamun ฦarfafawa na aikin ฦwayar cuta.
"Hanyoyin amsawa ciki har da marasa lafiya tare da ฦananan ciwace-ciwacen ฦwayar cuta na PD-L1 da aka gani a cikin wannan bincike na farko yana ฦarfafawa sosai da kuma tallafawa yiwuwar TTX-030 don tasiri ga ma'auni na kulawa ga marasa lafiya da ciwon ciki da kuma gastroesophageal ciwon daji," in ji Zev Wainberg, MD. Farfesa na Magunguna a UCLA kuma darektan UCLA GI Oncology Program. "Muna sa ran samun cikakken sakamakon wannan gwaji da kuma ci gaban wannan kyakkyawar hanyar magani."
An gabatar da ingantaccen sakamako na farko da aminci kamar yadda aka yanke bayanan wucin gadi na Maris 1, 2022. An yi rajistar marasa lafiya 44 duka. Marasa lafiya ashirin da shida (26) har yanzu suna kan jiyya na nazarin, kuma tsawon lokaci akan binciken shine kwanaki 214 (kewayon 8-464 + kwanaki). Daga cikin marasa lafiya na 40 masu inganci, marasa lafiya 21 (marasa lafiya 25 ciki har da waษanda ba a tabbatar da su ba) sun sami mafi kyawun amsawar juzu'i na juzu'i ko mafi kyau ciki har da 4 CRs: ORR = 52.5% (62,5% ciki har da wanda ba a tabbatar da shi ba), da ฦimar kula da cututtuka = โโ92.5%. Talatin da bakwai (37) na inganci-ฦimar marasa lafiya sun san PD-L1 Combined Positive Score (CPS); Yawan amsawa a cikin marasa lafiya tare da CPS โฅ1 sun kasance 65% (77% ciki har da waษanda ba a tabbatar da su ba).
Ashirin da bakwai na marasa lafiya na 44 (61%) sun sami akalla wani abu mara kyau (AE) na kowane matsayi da aka yi la'akari da TTX-030 (kimanin mai bincike), ciki har da marasa lafiya 9 (20.5%) tare da Grade 3 / 4 AEs. Abubuwan da ba su da kyau sun yi daidai da waษanda aka gani tare da daidaitattun kulawa (chemotherapy da anti-PD-1).
Anil Singhal, Babban Jami'in Gudanarwa ya ce "Bayanan mu da aka ba da haske a AACR suna wakiltar alamun farko na asibiti na rigakafin CD39 a cikin marasa lafiya da ciwon daji na ciki kuma suna tallafawa rawar TTX-030 don juyar da maganin rigakafi na adenosine," in ji Anil Singhal, Babban Jami'in Gudanarwa. "Muna sa ran ci gaba da ci gaban wannan binciken na asibiti na TTX-030, wanda muka yi imanin yana da yuwuwar inganta yanayin jiyya ga masu cutar kansa."
